Astellas Pharma US, Inc. is engaged in developing treatments for rare diseases, with 19 FDA-approved drugs and 3 orphan drug designations across conditions like acute intermittent porphyria and multiple organ dysfunction syndrome.
3
Orphan Designations
19
FDA Approvals
10
Rare Diseases
0
News Articles
| Disease | Drug(s) | Designation | Approved |
|---|---|---|---|
| acute intermittent porphyria | (2Z)-2-cyano-3-3hydroxy-N-[4-(trifluoromethly)phenyl]-2-hepten-6-ynamide | Orphan Designation | - |
| acute myeloid leukemia | XOSPATA | Orphan Designation | - |
| acute stress disorder | (2Z)-2-cyano-3-3hydroxy-N-[4-(trifluoromethly)phenyl]-2-hepten-6-ynamide | Orphan Designation | - |
| adult neuronal ceroid lipofuscinosis | XOSPATA | Orphan Designation | - |
| adult pleomorphic rhabdomyosarcoma | XOSPATA | Orphan Designation | - |
| multiple organ dysfunction syndrome | Prograf | Orphan Designation | - |
| primary adult heart tumor | XOSPATA | Orphan Designation | - |
| primary organ-specific lymphoma | Prograf | Orphan Designation | - |
| sensory organ benign neoplasm | Prograf | Orphan Designation | - |
| yellow fever | (2Z)-2-cyano-3-3hydroxy-N-[4-(trifluoromethly)phenyl]-2-hepten-6-ynamide | Orphan Designation | - |